University of Nottingham scientists have developed a new quantum therapeutic approach to treating cancer that could treat one of the most aggressive types of brain cancer, glioblastoma. The researchers created a new spray treatment capable of treating glioblastoma through quantum signaling, making their treatment the first-ever, quantum-therapy-based treatment.
This unique treatment works by changing neural cells at a quantum level via bio-nanoantennas, nano-particles of gold coated in redox-active molecules. According to the researchers, the novel treatment involves spraying glioblastoma tumor sites with bio-nanoantennae followed by the application of an electric field.
University of Nottingham research fellow and study coauthor Frannkie Rawson says the team refers to the spray as a “bio-nanoantennae” because they have the ability to “convert an electric field into a biological signaling event.”
Rawson and his team suggest that cancer cells quickly absorb the bio-nanoantennae once they are applied to tumor sites. Once an electrical field is applied, a quantum electron transfer occurs at the surface of cytochrome c, a protein bound to the bio-nanoantennae, modifying cytochrome c’s redox state and prompting cancer cells to activate cell death.
Published in the journal “Nature Nanotechnology,” the new research leverages a quantum tunneling phenomenon called Quantum Biological Electron Transfer (QBET). This unique treatment opens up a new avenue in the treatment of glioblastoma, an extremely hard-to-treat type of brain cancer with very low survival rates.
Glioblastomas originate in the spinal cord or brain before quickly proliferating into and destroying healthy tissue. The speed with which glioblastomas spread and their proximity to critical brain tissue makes them incredibly difficult to remove via surgery, chemotherapy or radiology, giving glioblastoma one of the lowest post-diagnosis survival rates (12 to 18 months).
Rawson explains that the new quantum-based treatment does not harm any adjacent healthy cells, making it significantly more effective than treatments such as chemotherapy and radiation, which often damage adjacent healthy tissue and cause various side effects.
However, Rawson said the research team still doesn’t have a full understanding of the mechanisms that make bio-nanoantennae in cancer cells sensitive to electric fields. He said that based on the team’s data, cancer cells seemed to have altered genetic expressions in relation to acute stress response when compared to normal brain cells. This may be the reason why the quantum therapy only affected tumor cells but had no impact on adjacent healthy brain tissue as electric field changes in the cell constitute an acute stress response.
Quantum therapy could be an exciting complement to the brain cancer drugs that are being developed by numerous entities, such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP). No single treatment option can suit all patients, so the more options, the better.
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN